PROSTATE CANCER is one of the most common forms of cancer in men, accounting for 44.4 percent of all cancers alongside lung, prostate and colorectal in 2018. A new immunotherapy drug has shown promise for prostate cancer sufferers in advanced stages of the disease.
You Can See More: Prostate cancer: How new immunotherapy can help men with ‘very poor’ prognosis
The following article Prostate cancer: How new immunotherapy can help men with ‘very poor’ prognosis is courtesy of Daily Express :: Health Feed
PROSTATE CANCER is one of the most common forms of cancer in men, accounting for 44.4 percent of all cancers alongside lung, prostate and colorectal in 2018. A new immunotherapy drug has shown promise for prostate cancer sufferers in advanced stages of the disease.
PROSTATE CANCER is one of the most common forms of cancer in men, accounting for 44.4 percent of all cancers alongside lung, prostate and colorectal in 2018. A new immunotherapy drug has shown promise for prostate cancer sufferers in advanced stages of the disease.
0 comments:
Post a Comment
Note: Only a member of this blog may post a comment.